Black Americans face the highest risk of developing Alzheimer’s disease and related dementias in the United States, at roughly twice the rate of non-Hispanic White Americans. Hispanic and Latino Americans also face elevated risk, with rates about 1.5 times higher than White Americans. These disparities are driven less by genetic differences and more by a web of social, economic, and health-related factors that accumulate over a lifetime.
How Risk Breaks Down by Race
Multiple large studies consistently place Black Americans at the top of the risk scale. A systematic review and meta-analysis published in the Journal of Alzheimer’s Disease found that even after adjusting for conditions like hypertension, diabetes, heart disease, and education level, Black Americans still had significantly higher dementia rates than White Americans. One well-known study from that review reported a hazard ratio of 2.4 for Black participants and 2.0 for Caribbean Hispanic participants compared to White participants, meaning their likelihood of developing Alzheimer’s was roughly double.
Hispanic and Latino Americans face the second-highest risk. The National Institute on Aging projects that by 2060, about 3.5 million Latinos in the U.S. will have Alzheimer’s or a related dementia, the largest increase of any racial or ethnic group. Much of that increase is simply demographic: the Latino population over age 65 is expected to nearly quadruple by 2060, and aging is the single biggest risk factor for dementia. But beyond population growth, higher rates of diabetes, high blood pressure, obesity, and depression in Latino communities add to the burden.
Asian Americans, by contrast, tend to have dementia rates similar to or lower than White Americans in most studies.
Why the Gap Exists
The racial gap in Alzheimer’s is not primarily a story about genetics. Researchers increasingly point to social and structural factors that create a self-reinforcing cycle of risk. A community-based study published in Alzheimer’s & Dementia identified structural racism as what the authors called an “external yet ubiquitous” force that accelerates other drivers of dementia, including poverty, insufficient community investment, and lower-quality healthcare.
The chain works like this: economic hardship, especially low income and unemployment, reduces access to both physical and mental healthcare. That means chronic conditions like hypertension and diabetes go undiagnosed or poorly managed for longer. Those conditions, in turn, damage blood vessels in the brain over decades. Researchers at the National Institute on Aging have noted that vascular and social pathways seem to drive Alzheimer’s risk in Black and Latino populations more than the genetic pathways that are more common in White populations. In practical terms, cardiovascular risk factors appear to accelerate cognitive decline in these groups even more than in White Americans.
Neighborhood matters too. In the Alzheimer’s & Dementia study, workshop participants from more disadvantaged neighborhoods were more likely to emphasize stress, poor diet, and limited healthcare access as major concerns, highlighting how the environment people live in shapes both their risk and their awareness of it.
The Role of Cardiovascular Health
Conditions like high blood pressure, diabetes, and heart disease are more common in Black and Hispanic communities, and all of them raise dementia risk. Hypertension in midlife is one of the strongest modifiable risk factors for Alzheimer’s, and Black Americans develop high blood pressure earlier, more frequently, and more severely than other groups. Diabetes, which is also more prevalent in Black and Latino populations, is independently linked to faster cognitive decline.
The encouraging side of this is that vascular risk factors are treatable. As one researcher studying Latino populations put it: if vascular contributions are a major driver of cognitive impairment, “that’s bad news. But the good news is that you can do something about that by improving cardiovascular health.” Managing blood pressure, blood sugar, and weight in midlife can meaningfully reduce dementia risk later.
Later Diagnosis, More Advanced Disease
Racial disparities don’t just affect who gets Alzheimer’s. They also affect when it’s caught. Black and Hispanic Americans are typically diagnosed at a more advanced stage of the disease than White Americans. At the time of diagnosis, non-Hispanic Black and Hispanic patients show poorer cognitive function and more difficulty with daily activities compared to their White peers.
The delays are measurable. When a diagnosis is delayed, Black Americans wait an average of about 35 months, and Hispanic Americans wait nearly 44 months, compared to 31 months for White Americans. Those extra months and years without a diagnosis mean lost time for treatment, planning, and support. They also mean caregivers and families are managing more severe symptoms by the time help arrives.
Underrepresentation in Treatment Research
The communities most affected by Alzheimer’s are the least represented in the clinical trials developing new treatments. Across 113 Alzheimer’s drug trials with complete racial data, Black participants made up only 4.8% of enrollees, roughly half of what their share of the patient population would warrant. This means the drugs reaching the market, including the recently approved therapies designed to slow disease progression, have been tested predominantly in White and Asian populations.
This gap matters because Alzheimer’s may progress differently and respond differently to treatment depending on whether it’s driven more by vascular pathways or genetic pathways. A drug tested mostly in populations where genetic risk dominates may not work as well in populations where cardiovascular and social factors play a larger role. Until trials reflect the actual patient population, the effectiveness of new treatments for the people who need them most remains an open question.